• A phase I trial has recently evaluated enzalutamide

  2023-02-13

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• In our previous work diffuse deposition patterns of

  2023-02-13

  

  In our previous work, diffuse deposition patterns of neocortical Aβ and a hierarchical upward spreading pattern of tau were determined with in vivo 18F-florbetaben and 18F-flortaucipir positron emission tomography (PET) studies, based on the regional frequency of involvement by tau and Aβ (Cho et al

• It is noteworthy to mention the limitations

  2023-02-13

  

  It is noteworthy to mention the limitations of this study like tPA plus LB1 treatment beyond 4 h after stroke was not investigated. Especially 6 or 8 h after stroke could be studied in future projects for translational purposes. Second drawback might be that we performed the experiments in different

• br Discussion In a series

  2023-02-13

  

  Discussion In a series of linear mixed effects models of longitudinal neuroanatomical change, we have identified genetic risk variants associated with an increase in NK 252 shape asymmetry in AD. The closest genes associated with significant SNPs include BIN1 (rs6733839), CD2AP (rs10948363), and

• Another research group assessed pairs of middle aged years

  2023-02-13

  

  Another research group assessed 8503 pairs of middle-aged (Ketorolac receptor the twin exposed to surgery had lower scores on cognitive tests in 49% of the pairs. Twins aged 70 and older who underwent hip and knee arthroplasty scored higher on cognitive tests, even higher than those who had not unde

• Further evidence for action mechanism was provided by

  2023-02-13

  

  Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t

• The disease stimulatory effects of hyperadiponectinemia in p

  2023-02-13

  

  The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in

• br Conflict of interest br Financial support br Acknowledgme

  2023-02-13

  

  Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros

• Finasteride was the first steroidal reductase inhibitor appr

  2023-02-10

  

  Finasteride (13) was the first steroidal 5α-reductase inhibitor approved by the US Food and Drug Administration (FDA) in 1992 for treatment of BPH. In fact, long term clinical studies with this drug demonstrated a sustained reduction of the prostatic specific antigen and an overall improvement in BH

• The diagnosis of ICP is

  2023-02-10

  

  The diagnosis of ICP is currently based on the presence of pruritus, raised fasting serum TBS levels above 10μmol/L, and/or elevated serum transaminases (in the absence of diseases that cause cholestasis or pruritus) as well as spontaneous relief of signs and symptoms within four to six weeks after

• Many ruthenium complexes were tested

  2023-02-10

  

  Many ruthenium complexes were tested as potential anticancer agents and two complexes, namely NAMI-A (trans-[imH] [RuCl4(dmso-S)(im)]; im, imidazole) and KP1019 (trans-[indH][RuCl4(ind)2]; ind, indazole) have successfully entered clinical trials [27], [28]. NAMI-A is selectively active against metas

• C-type natriuretic peptide (1-22) (human, rat, swine) To fur

  2023-02-10

  

  To further address the mechanism of Didox’s suppressive effects on mast cell activation, FceRI receptor C-type natriuretic peptide (1-22) (human, rat, swine) and downstream transcription factor induction were assessed. We found that Didox had no effect on FceRI surface expression, and thus conclude

• It has been proposed that angiotensin II Ang II

  2023-02-10

  

  It has been proposed that angiotensin II (Ang II) may upregulate COX-2 expression and the subsequent vasoconstrictor prostanoids production through the activation of AT-1 receptors in vascular smooth muscle cells (Hu et al., 2002). Additionally, this peptide is also able to stimulate the generation

• In this report we introduce a new method

  2023-02-10

  

  In this report, we introduce a new method for identifying aminopeptidases. Because single substrates can be insufficient for enzyme identification, we used an entire library of substrates to obtain more information about enzyme activity and to directly detect aminopeptidases. Moreover, substrates ca

• For comprehensive understanding of actin myosin

  2023-02-08

  

  For comprehensive understanding of actin-myosin XI as a control network, it will be necessary to determine the functions of all the myosin XI and why not isoforms. However, it is difficult to reveal the function of individual myosin XI isoforms because most myosin XI single knockouts exhibited no si

14647 records 325/977 page Previous Next First page 上5页 321322323324325 下5页 Last page